X4 Pharmaceuticals (XFOR) Retained Earnings (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported Retained Earnings of -$109000.0 for Q4 2025, up 10.66% on a YoY basis from -$98503.7 in Q4 2024, and up 99.98% quarter-over-quarter from -$570.6 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Retained Earnings (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Retained Earnings for 9 years, with the latest figure at -$109000.0 in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 10.66% year-over-year to -$109000.0; the trailing twelve-month figure through Dec 2025 stood at -$109000.0 (up 10.66% YoY), and the FY2025 full-year result was -$109000.0, up 10.66% from the prior year.
- Retained Earnings for Q4 2025 stood at -$109000.0, up from -$570.6 million in the prior quarter.
- The five-year high for Retained Earnings was -$109000.0 in Q4 2025, with the low at -$570.6 million in Q3 2025.
- Historically, Retained Earnings has averaged -$222.3 million across 5 years, with a median of -$222.7 million in 2021.
- The largest YoY upside for Retained Earnings was 99.97% in 2024 against a maximum downside of 445026.05% in 2024.
- X4 Pharmaceuticals' Retained Earnings stood at -$282.9 million in 2021, then surged by 99.96% to -$119000.0 in 2022, then tumbled by 401500.84% to -$477.9 million in 2023, then jumped by 99.97% to -$122000.0 in 2024, then climbed by 10.66% to -$109000.0 in 2025.
- The last three Retained Earnings figures came in at -$109000.0 (Q4 2025), -$570.6 million (Q3 2025), and -$138000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -838.07 Mn |
| 10 | X4 Pharmaceuticals | 166.63 Mn | 166.63 Mn | 2.20 Mn | -109,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -109,000.00 |
| Sep 30, 2025 | -570.60 Mn |
| Jun 30, 2025 | -138,000.00 |
| Mar 31, 2025 | -515.07 Mn |
| Dec 31, 2024 | -122,000.00 |
| Sep 30, 2024 | -475.50 Mn |
| Jun 30, 2024 | -438.84 Mn |
| Mar 31, 2024 | -529.70 Mn |
| Dec 31, 2023 | -477.91 Mn |
| Sep 30, 2023 | -119,000.00 |
| Jun 30, 2023 | -456.47 Mn |
| Mar 31, 2023 | -119,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Sep 30, 2022 | -119,000.00 |
| Jun 30, 2022 | -119,000.00 |
| Mar 31, 2022 | -119,000.00 |
| Dec 31, 2021 | -282.87 Mn |
| Sep 30, 2021 | -252.66 Mn |
| Jun 30, 2021 | -232.49 Mn |
| Mar 31, 2021 | -212.85 Mn |